A new combination of blood test and fibroscan for accurate non-invasive diagnosis of liver fibrosis stages in chronic hepatitis C

American Journal of Gastroenterology

Volumn 106, Issue 7, 2011, Pages 1255-1263

  Boursier, Jérme ^a,b,c   De Ledinghen, Victor ^d,e   Zarski, Jean Pierre ^f,g   Rousselet, Marie Christine ^a,b,c   Sturm, Nathalie ^f   Foucher, Juliette ^d   Leroy, Vincent ^f   Fouchard Hubert, Isabelle ^a,b,c   Bertrais, Sandrine ^b,c   Gallois, Yves ^a,b,c   Oberti, Frédéric ^a,b,c   Dib, Nina ^a,b,c   Calès, Paul ^a,b,c  

^a ANGERS UNIVERSITY HOSPITAL   (France)

^b UNIVERSITÉ D'ANGERS   (France)

^c Pres UNAM   (France)

^d Service D ' H é Pato Gastroent é Rologie   (France)

^e INSERM   (France)

^f GRENOBLE UNIVERSITY HOSPITAL   (France)

^g UNIV GRENOBLE ALPES   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; ARTICLE; CLINICAL PRACTICE; COST EFFECTIVENESS ANALYSIS; DIAGNOSTIC ACCURACY; DIAGNOSTIC ERROR; DIAGNOSTIC TEST; DIAGNOSTIC TEST ACCURACY STUDY; DISEASE CLASSIFICATION; FEMALE; FIBROMETER; FIBROSCAN; FIBROTEST; HEALTH CARE COST; HEPATITIS C; HUMAN; HUMAN TISSUE; LIVER BIOPSY; LIVER FIBROSIS; LIVER HISTOLOGY; MAJOR CLINICAL STUDY; MALE; PREDICTIVE VALUE; PRIORITY JOURNAL; PROSPECTIVE STUDY; SENSITIVITY AND SPECIFICITY;

ADULT; ELASTICITY IMAGING TECHNIQUES; FEMALE; HEMATOLOGIC TESTS; HEPATITIS C, CHRONIC; HUMANS; LIVER CIRRHOSIS; LOGISTIC MODELS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX;

EID: 79960034041     PISSN: 00029270     EISSN: 15720241     Source Type: Journal    
DOI: 10.1038/ajg.2011.100     Document Type: Article

References (34)

1. Ghany MC, Strader DB, Thomas DL et al. American Association for the Study of Liver Diseases. Diagnosis, management, and treatment of hepatitis C: an update. Hepatology 2009; 49: 1335-74.
2. Everhart JE, Wright EC, Goodman ZD et al. Prognostic value of Ishak fibrosis stage: findings from the hepatitis C antiviral long-term treatment against cirrhosis trial. Hepatology 2010; 51: 585-94.
3. Rousselet MC, Michalak S, Dupre F et al. Sources of variability in histological scoring of chronic viral hepatitis. Hepatology 2005; 41: 257-64. (Pubitemid 40165369)
4. Cales P, Boursier J, Oberti F et al. FibroMeters: a family of blood tests for liver fibrosis. Gastroenterol Clin Biol 2008; 32: 40-51.
5. Castera L, Forns X, Alberti A. Non-invasive evaluation of liver fibrosis using transient elastography. J Hepatol 2008; 48: 835-47.
6. Halfon P, Munteanu M, Poynard T. FibroTest-ActiTest as a non-invasive marker of liver fibrosis. Gastroenterol Clin Biol 2008; 32: 22-39.
7. Leroy V. Other non-invasive markers of liver fibrosis. Gastroenterol Clin Biol 2008; 32: 52-7.
8. Calès P, Boursier J, Bertrais S et al. Accuracy of liver fibrosis classifications provided by non-invasive tests. J Hepatol 2010; 52 (Suppl 1): S406.
9. Boursier J, Bacq Y, Halfon P et al. Improved diagnostic accuracy of blood tests for severe fibrosis and cirrhosis in chronic hepatitis C. Eur J Gastroenterol Hepatol 2009; 21: 28-38.
10. Cales P, de Ledinghen V, Halfon P et al. Evaluating the accuracy and increasing the reliable diagnosis rate of blood tests for liver fibrosis in chronic hepatitis C. Liver Int 2008; 28: 1352-62.
11. Cales P, Boursier J, de Ledinghen V et al. Evaluation and improvement of a reliable diagnosis of cirrhosis by blood tests. Gastroenterol Clin Biol 2008; 32: 1050-60.
12. Boursier J, Vergniol J, Sawadogo A et al. The combination of a blood test and Fibroscan improves the non-invasive diagnosis of liver fibrosis. Liver Int 2009; 29: 1507-15.
13. Zarski JP, Sturm N, Guechot J et al. Prospective independent validation and comparison of 10 biomarkers and transient elastography (Fibroscan TM ) for liver fibrosis assessment in patients with chronic hepatitis C. J Hepatol 2010; 52: S175.
14. Nousbaum JB, Cadranel JF, Bonnemaison G e t al. Clinical practice guidelines on the use of liver biopsy. Gastroenterol Clin Biol 2002; 26: 848-78. (Pubitemid 35334246)
15. Castera L, Vergniol J, Foucher J e t al. Prospective comparison of transient elastography, Fibrotest, APRI, and liver biopsy for the assessment of fibrosis in chronic hepatitis C. Gastroenterology 2005; 128: 343-50. (Pubitemid 40439195)
16. Leroy V, Halfon P, Bacq Y et al. Diagnostic accuracy, reproducibility and robustness of fibrosis blood tests in chronic hepatitis C: a meta-analysis with individual data. Clin Biochem 2008; 41: 1368-76.
17. Adams LA, Bulsara M, Rossi E et al. Hepascore: an accurate validated predictor of liver fibrosis in chronic hepatitis C infection. Clin Chem 2005; 51: 1867-73. (Pubitemid 41368177)
18. Sterling RK, Lissen E, Clumeck N et al. Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfection. Hepatology 2006; 43: 1317-25. (Pubitemid 43980111)
19. Wai CT, Greenson JK, Fontana RJ et al. A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C. Hepatology 2003; 38: 518-26. (Pubitemid 36919874)
20. Lucidarme D, Foucher J, Le Bail B et al. Factors of accuracy of transient elastography (fibroscan) for the diagnosis of liver fibrosis in chronic hepatitis C. Hepatology 2009; 49: 1083-9.
21. de Ledinghen V, Vergniol J. Transient elastography (FibroScan). Gastroenterol Clin Biol 2008; 32: 58-67.
22. Poynard T, Imbert-Bismut F, Munteanu M et al. Overview of the diagnostic value of biochemical markers of liver fibrosis (FibroTest, HCV FibroSure) and necrosis (ActiTest) in patients with chronic hepatitis C. Comp Hepatol 2004; 3: 8.
23. Thein HH, Yi Q, Dore GJ et al. Estimation of stage-specific fibrosis progression rates in chronic hepatitis C virus infection: a meta-analysis and metaregression. Hepatology 2008; 48: 418-31.
24. Poynard T, Halfon P, Castera L et al. Standardization of ROC curve areas for diagnostic evaluation of liver fibrosis markers based on prevalences of fibrosis stages. Clin Chem 2007; 53: 1615-22. (Pubitemid 47340057)
25. Mehta SH, Lau B, Afdhal NH et al. Exceeding the limits of liver histology markers. J Hepatol 2009; 50: 36-41.
26. Sebastiani G, Vario A, Guido M et al. Stepwise combination algorithms of non-invasive markers to diagnose significant fibrosis in chronic hepatitis C. J Hepatol 2006; 44: 686-93.
27. Castera L, Sebastiani G, Le Bail B et al. Prospective comparison of two algorithms combining non-invasive methods for staging liver fibrosis in chronic hepatitis C. J Hepatol 2010; 52: 191-8.
28. Sebastiani G, Halfon P, Castera L et al. SAFE biopsy: a validated method for large-scale staging of liver fibrosis in chronic hepatitis C. Hepatology 2009; 49: 1821-7.
29. Bedossa P, Carrat F. Liver biopsy: the best, not the gold standard. J Hepatol 2009; 50: 1-3.
30. Bourliere M, Penaranda G, Renou C et al. Validation and comparison of indexes for fibrosis and cirrhosis prediction in chronic hepatitis C patients: proposal for a pragmatic approach classification without liver biopsies. J Viral Hepat 2006; 13: 659-70. (Pubitemid 44401194)
31. Halfon P, Bourliere M, Deydier R e t al. Independent prospective multicenter validation of biochemical markers (fibrotest-actitest) for the prediction of liver fibrosis and activity in patients with chronic hepatitis C: the fibropaca study. Am J Gastroenterol 2006; 101: 547-55. (Pubitemid 43340931)
32. Poynard T, Munteanu M, Imbert-Bismut F et al. Prospective analysis of discordant results between biochemical markers and biopsy in patients with chronic hepatitis C. Clin Chem 2004; 50: 1344-55. (Pubitemid 38970641)
33. Myers RP, Crotty P, Pomier-Layrargues G e t al. Prevalence, risk factors and causes of discordances in fibrosis staging by transient elastography and liver biopsy. Liver Int 2010; 30: 1471-80.
34. Cal è s P, Oberti F, Michalak S et al. A novel panel of blood markers to assess the degree of liver fibrosis. Hepatology 2005; 42: 1373-81. (Pubitemid 43260040)